Article

Dr. Boyer joins iCo strategic advisory board

Vancouver, British Columbia-iCo Therapeutics Inc. announced that David S. Boyer, MD, will join its strategic advisory team.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
ASRS 2025: 48-month results from OAKS, DERBY, and GALE open-label extension
August 9th 2025

ASRS 2025: 48-month results from OAKS, DERBY, and GALE open-label extension

3 Things You Should Know About the GA Pipeline
August 9th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Cosmetic procedures associated with serious ophthalmologic complications
August 9th 2025

Cosmetic procedures associated with serious ophthalmologic complications

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 9th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program
August 9th 2025

Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan
August 9th 2025

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan

© 2025 MJH Life Sciences

All rights reserved.